F2-isoprostanes from arachidonic acid -: Biomarkers of oxidative stress?

被引:0
|
作者
Schmandke, H
机构
来源
ERNAHRUNGS UMSCHAU | 2000年 / 47卷 / 05期
关键词
F-2-isoprostanes; biomarkers; oxidative stress;
D O I
暂无
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
F-2-isoprostanes (F-2-IsoP) are prostaglandin isomers formed from arachidonic acid in a cyclooxigenase-independent free radical-catalyzed mechanism. Therefore they are potential indicators of oxidative stress. From the theoretically possible 64 isomers hitherto 15-F-2t- IsoP, 5-F-2t-IsoP, 5-F-2c-IsoP and 5-epi-5-F-2c-IsoP have been identified in humans. F-2-IsoP undergo beta-oxidation. 2,3-Diner-15 F-2t and 2,3-Diaor-5,6-dihydro-15-F-2t-IsoP are the identified metabolites. 15-F-2t IsoP is a potent smooth muscle cell constrictor modulating platelets as well as inducing proliferation of vascular smooth muscle cells. F-2t IsoP are measured after chromatographic purification by GC/MS, immune-enzyme or radioimmuno-assays. 15-F-2t-IsoP has been found in blood plasma, atherosclerotic lesions and urine of humans, 5-F-2t-IsoP in blood plasma and urine. 5-F-2c- and 5-epi-5-F-2c-IsoP were identified in urine. In the case ofnon-insuline dependent diabetes mellitus and smokers, the 15-F-2t-IsoP values are increased in blood plasma, atherosclerotic lesions and in that of hypercholesterolemia in LDL. in urine the amounts of 15-F-2t- and 5-F-2t-IsoP are increased in smokers and hypercholesterolemic persons. ol-Tocopherol supplementation decreases the urinary content of F-2-IsoP to normal levels. Supplementation of soy isoflavonoids does not influence urine level of F-2-IsoP in subjects with high-normal blood pressure. Urinary 15-F-2t-TsoP excretion is not dependent on the lipid content of the diet, but increased by a 24 h fasting period. A correlation between oxidative stress and risk factors for coronary heart disease is obvious.
引用
收藏
页码:172 / +
页数:6
相关论文
共 50 条
  • [31] Hyperbaric oxygen therapy is not associated with oxidative stress assessed using plasma F2-isoprostanes and isofurans
    Corcoran, Tomas
    Ting, Sonya
    Mas, Emilie
    Phillips, Michael
    O'Loughlin, Edmond
    Barden, Anne
    Mori, Trevor A.
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2017, 127 : 16 - 19
  • [32] F2-Isoprostanes as Biomarkers of Late-onset Alzheimer’s Disease
    Thomas J. Montine
    Joseph Quinn
    Jeffrey Kaye
    Jason D. Morrow
    Journal of Molecular Neuroscience, 2007, 33 : 114 - 119
  • [33] Aerobic training reduces systemic oxidative stress in young women with elevated levels of F2-isoprostanes
    Arikawa, Andrea Y.
    Thomas, William
    Gross, Myron
    Smith, Alma
    Phipps, William R.
    Kurzer, Mindy S.
    Schmitz, Kathryn H.
    CONTEMPORARY CLINICAL TRIALS, 2013, 34 (02) : 212 - 217
  • [34] F2-Isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure
    Wiswedel, I
    Hirsch, D
    Carluccio, F
    Hampl, H
    Siems, W
    BIOFACTORS, 2005, 24 (1-4) : 201 - 208
  • [35] From Biomarker to Mechanism? F2-isoprostanes in Pulmonary Fibrosis
    Thatcher, Thomas H.
    Peters-Golden, Marc
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 206 (05) : 530 - 532
  • [36] F2-Isoprostanes and Adiposity in Older Adults
    Kanaya, Alka M.
    Wassel, Christina L.
    Stoddard, Pamela J.
    Harris, Tamara B.
    Cummings, Steven R.
    Kritchevsky, Stephen B.
    Goodpaster, Bret H.
    Green, Christie
    Satterfield, Suzanne
    Gross, Myron D.
    OBESITY, 2011, 19 (04) : 861 - 867
  • [37] F2-Isoprostanes, tocopherols and normal pregnancy
    Palm, Maria
    Axelsson, Ove
    Wernroth, Lisa
    Basu, Samar
    FREE RADICAL RESEARCH, 2009, 43 (06) : 546 - 552
  • [38] F2-isoprostanes:: Review of analytical methods
    Berdeaux, O
    Scruel, O
    Cracowski, JL
    Durand, T
    CURRENT PHARMACEUTICAL ANALYSIS, 2006, 2 (01) : 69 - 78
  • [39] F2-Isoprostanes and Adiposity in Older Adults
    Kanayk, Alka M.
    Wassel, Christina L.
    Harris, Tamara
    Cummings, Steven R.
    Kritchevsky, Steve
    Goodpaster, Bret
    Satter-Field, Suzanne
    Gross, Myron
    DIABETES, 2009, 58 : A256 - A256
  • [40] Elevated F2-isoprostanes in thalassemic patients
    Matayatsuk, Chutima
    Lee, Chung-Yung J.
    Kalpravidh, Ruchaneekorn W.
    Sirankapracha, Pornpan
    Wilairat, Prapin
    Fucharoen, Suthat
    Halliwell, Barry
    FREE RADICAL BIOLOGY AND MEDICINE, 2007, 43 (12) : 1649 - 1655